Reiter Y - Search Results

1

Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo.

Novak H, Noy R, Oved K, Segal D, Wels WS, Reiter Y. Novak H, et al. Among authors: reiter y. Int J Cancer. 2007 Jan 15;120(2):329-36. doi: 10.1002/ijc.22168. Int J Cancer. 2007. PMID: 17066453

2

Construction of a functional disulfide-stabilized TCR Fv indicates that antibody and TCR Fv frameworks are very similar in structure.

Reiter Y, Kurucz I, Brinkmann U, Jung SH, Lee B, Segal DM, Pastan I. Reiter Y, et al. Immunity. 1995 Mar;2(3):281-7. doi: 10.1016/1074-7613(95)90052-7. Immunity. 1995. PMID: 7697545 Free article.

3

Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.

Reiter Y, Kreitman RJ, Brinkmann U, Pastan I. Reiter Y, et al. Int J Cancer. 1994 Jul 1;58(1):142-9. doi: 10.1002/ijc.2910580123. Int J Cancer. 1994. PMID: 8014011

4

Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.

Reiter Y, Wright AF, Tonge DW, Pastan I. Reiter Y, et al. Int J Cancer. 1996 Jul 3;67(1):113-23. doi: 10.1002/(SICI)1097-0215(19960703)67:1<113::AID-IJC19>3.0.CO;2-F. Int J Cancer. 1996. PMID: 8690511

5

Recombinant human single-chain MHC-peptide complexes made from E. coli By in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens.

Denkberg G, Cohen CJ, Segal D, Kirkin AF, Reiter Y. Denkberg G, et al. Among authors: reiter y. Eur J Immunol. 2000 Dec;30(12):3522-32. doi: 10.1002/1521-4141(2000012)30:12<3522::AID-IMMU3522>3.0.CO;2-D. Eur J Immunol. 2000. PMID: 11093172 Free article.

6

Recombinant immunotoxins in targeted cancer cell therapy.

Reiter Y. Reiter Y. Adv Cancer Res. 2001;81:93-124. doi: 10.1016/s0065-230x(01)81003-4. Adv Cancer Res. 2001. PMID: 11430597 Review.

7

Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins.

Niv R, Cohen CJ, Denkberg G, Segal D, Reiter Y. Niv R, et al. Among authors: reiter y. Curr Pharm Biotechnol. 2001 Mar;2(1):19-46. doi: 10.2174/1389201013378824. Curr Pharm Biotechnol. 2001. PMID: 11482347 Review.

8

Targeting multidrug resistant tumor cells with a recombinant single-chain FV fragment directed to P-glycoprotein.

Niv R, Assaraf YG, Segal D, Pirak E, Reiter Y. Niv R, et al. Among authors: reiter y. Int J Cancer. 2001 Dec 15;94(6):864-72. doi: 10.1002/ijc.1552. Int J Cancer. 2001. PMID: 11745490

9

Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.

Lev A, Denkberg G, Cohen CJ, Tzukerman M, Skorecki KL, Chames P, Hoogenboom HR, Reiter Y. Lev A, et al. Among authors: reiter y. Cancer Res. 2002 Jun 1;62(11):3184-94. Cancer Res. 2002. PMID: 12036932

10

Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.

Lev A, Novak H, Segal D, Reiter Y. Lev A, et al. Among authors: reiter y. J Immunol. 2002 Sep 15;169(6):2988-96. doi: 10.4049/jimmunol.169.6.2988. J Immunol. 2002. PMID: 12218113

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

106 results

Search Page

Filters